Spots Global Cancer Trial Database for resectable pancreatic adenocarcinoma
Every month we try and update this database with for resectable pancreatic adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer | NCT01389440 | Pancreatic Aden... | Gemcitabine and... | 18 Years - 75 Years | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Identify microRNAs in Cachexia in Pancreatic Carcinoma | NCT05275075 | Resectable Panc... | Pancreatic canc... | 18 Years - | University of Oklahoma | |
| Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma | NCT00600002 | Resectable Panc... Pancreatic Canc... | GM-CSF | 18 Years - | University of California, Irvine | |
| Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | NCT04340141 | Pancreatic Aden... Resectable Panc... Pancreatic Canc... | Oxaliplatin Irinotecan Hydr... Leucovorin Calc... Fluorouracil Resection Questionnaire A... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma | NCT03704662 | Pancreatic Canc... | Stereotactic Bo... Preoperative Fr... | 18 Years - | Medical College of Wisconsin | |
| Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer | NCT01389440 | Pancreatic Aden... | Gemcitabine and... | 18 Years - 75 Years | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | NCT04940286 | Borderline Rese... Resectable Panc... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... | Durvalumab Gemcitabine Nab-paclitaxel Oleclumab | 18 Years - | M.D. Anderson Cancer Center | |
| Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer | NCT03251365 | Resectable Panc... | HIPEC-gemcitabi... | 18 Years - | Hospital General de Ciudad Real | |
| Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | NCT04927780 | Pancreatic Canc... Pancreatic Duct... Resectable Panc... | Leucovorin Calc... Fluorouracil Irinotecan Hydr... Oxaliplatin Resection | 18 Years - | Erasmus Medical Center | |
| A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | NCT05066802 | Resectable Panc... | neoadjuvant mod... | 19 Years - | Yonsei University | |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | NCT03727880 | Resectable Panc... Pancreatic Duct... | Pembrolizumab Defactinib | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer | NCT06423326 | Borderline Rese... Resectable Panc... Stage I Pancrea... Stage II Pancre... Stage III Pancr... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Gemcitabine Magnetic Resona... Nab-paclitaxel Pancreatic Surg... | 18 Years - | Emory University | |
| Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma | NCT03318497 | Pancreatic Aden... | 3'-deoxy-3'-[F-... Computed Tomogr... Positron Emissi... Laboratory Biom... | 18 Years - | University of Texas Southwestern Medical Center | |
| Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer | NCT06168552 | Resectable Panc... | Injection of fl... | 18 Years - | Zhejiang University | |
| Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma | NCT03704662 | Pancreatic Canc... | Stereotactic Bo... Preoperative Fr... | 18 Years - | Medical College of Wisconsin | |
| Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis | NCT05754788 | Resectable Panc... | 18 Years - 80 Years | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | ||
| Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer | NCT04340141 | Pancreatic Aden... Resectable Panc... Pancreatic Canc... | Oxaliplatin Irinotecan Hydr... Leucovorin Calc... Fluorouracil Resection Questionnaire A... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer | NCT06423326 | Borderline Rese... Resectable Panc... Stage I Pancrea... Stage II Pancre... Stage III Pancr... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Gemcitabine Magnetic Resona... Nab-paclitaxel Pancreatic Surg... | 18 Years - | Emory University | |
| Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | NCT03727880 | Resectable Panc... Pancreatic Duct... | Pembrolizumab Defactinib | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Identify microRNAs in Cachexia in Pancreatic Carcinoma | NCT05275075 | Resectable Panc... | Pancreatic canc... | 18 Years - | University of Oklahoma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
